Equity Details
Price & Market Data
Price: $5.05
Daily Change: -$0.36 / 7.13%
Daily Range: $5.05 - $5.56
Market Cap: $440,149,024
Daily Volume: 310,187
Performance Metrics
1 Week: -1.79%
1 Month: -3.68%
3 Months: 32.21%
6 Months: 68.20%
1 Year: 85.81%
YTD: 54.06%
About Atea Pharmaceuticals, Inc. (AVIR)
Comprehensive financial data on Atea Pharmaceuticals, Inc. (AVIR). Trading at 5.05, it has a daily change of -$0.36 / 7.13%. Market cap: 440,149,024. Review its performance from the last week to the last year.
Company Details
Employees: 55
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.